Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech : Pfizer/BioNTech's COVID-19 Vaccine Safe In Five To 11 Years Old, Trial Shows

09/20/2021 | 07:15am EDT


© MT Newswires 2021
All news about BIONTECH SE
10/21Health Care Up As BioNTech Rallies -- Health Care Roundup
DJ
10/21PFIZER WILL SHIP MILLIONS OF VACCINE : Trudeau
AQ
10/21BIONTECH : Shares Rise After Data Shows Efficacy of COVID-19 Vaccine's Booster Dose
MT
10/21GLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
10/21Canada, Pfizer Strike Deal on Pediatric Vaccine Doses
DJ
10/21European ADRs Move Lower in Thursday Trading
MT
10/21PFIZER : BioNTech Say Phase 3 Trial Data Showed Efficacy of Their COVID-19 Vaccine's Boost..
MT
10/21MODERNA : EU regulator verdict on Moderna COVID-19 booster shot next week
RE
10/21BIONTECH : PFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID..
PU
10/21PFIZER : BioNTech Report Nearly 96% Efficacy from COVID-19 Vaccine Booster Dose
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 703 M 19 432 M 19 432 M
Net income 2021 8 797 M 10 234 M 10 234 M
Net cash 2021 8 661 M 10 076 M 10 076 M
P/E ratio 2021 7,01x
Yield 2021 -
Capitalization 59 493 M 69 162 M 69 213 M
EV / Sales 2021 3,04x
EV / Sales 2022 2,41x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 246,32 €
Average target price 254,64 €
Spread / Average Target 3,38%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE251.28%69 162
GILEAD SCIENCES, INC.14.98%83 993
WUXI APPTEC CO., LTD.25.77%65 142
REGENERON PHARMACEUTICALS17.86%59 196
VERTEX PHARMACEUTICALS-20.84%48 536
BEIGENE, LTD.45.24%35 024